WallStreetZenWallStreetZen

NASDAQ: SLRX
Salarius Pharmaceuticals Inc Stock

$0.53+0.04 (+8.16%)
Updated Mar 28, 2024
SLRX Price
$0.53
Fair Value Price
N/A
Market Cap
$2.28M
52 Week Low
$0.43
52 Week High
$2.68
P/E
-0.14x
P/B
0.43x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$12.54M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.25
Operating Cash Flow
-$13M
Beta
0.72
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A

SLRX Overview

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SLRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SLRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SLRX is good value based on its book value relative to its share price (0.43x), compared to the US Biotechnology industry average (6.21x)
P/B vs Industry Valuation
SLRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SLRX due diligence checks available for Premium users.

Be the first to know about important SLRX news, forecast changes, insider trades & much more!

SLRX News

Valuation

SLRX fair value

Fair Value of SLRX stock based on Discounted Cash Flow (DCF)
Price
$0.53
Fair Value
$4.45
Undervalued by
88.08%
SLRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SLRX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.14x
Industry
14.26x
Market
44.51x

SLRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.43x
Industry
6.21x
SLRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SLRX's financial health

Profit margin

Revenue
$0.0
Net Income
-$881.8k
Profit Margin
0%
SLRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$6.6M
Liabilities
$1.3M
Debt to equity
0.25
SLRX's short-term assets ($6.52M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SLRX's short-term assets ($6.52M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SLRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SLRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.5M
Investing
$0.0
Financing
-$169.4k
SLRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SLRX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SLRX$2.28M+9.07%-0.14x0.43x
SCNI$2.26M+3.80%-0.11x-0.84x
INM$2.20M+4.90%-0.29x0.17x
GRI$2.43M-2.06%-0.03x9.38x
QLGN$2.07M0.00%-0.11x-1.26x

Salarius Pharmaceuticals Stock FAQ

What is Salarius Pharmaceuticals's quote symbol?

(NASDAQ: SLRX) Salarius Pharmaceuticals trades on the NASDAQ under the ticker symbol SLRX. Salarius Pharmaceuticals stock quotes can also be displayed as NASDAQ: SLRX.

If you're new to stock investing, here's how to buy Salarius Pharmaceuticals stock.

What is the 52 week high and low for Salarius Pharmaceuticals (NASDAQ: SLRX)?

(NASDAQ: SLRX) Salarius Pharmaceuticals's 52-week high was $2.68, and its 52-week low was $0.43. It is currently -80.26% from its 52-week high and 23.02% from its 52-week low.

How much is Salarius Pharmaceuticals stock worth today?

(NASDAQ: SLRX) Salarius Pharmaceuticals currently has 4,314,433 outstanding shares. With Salarius Pharmaceuticals stock trading at $0.53 per share, the total value of Salarius Pharmaceuticals stock (market capitalization) is $2.28M.

Salarius Pharmaceuticals stock was originally listed at a price of $9,343.75 in Jan 29, 2015. If you had invested in Salarius Pharmaceuticals stock at $9,343.75, your return over the last 9 years would have been -99.99%, for an annualized return of -66.26% (not including any dividends or dividend reinvestments).

How much is Salarius Pharmaceuticals's stock price per share?

(NASDAQ: SLRX) Salarius Pharmaceuticals stock price per share is $0.53 today (as of Mar 28, 2024).

What is Salarius Pharmaceuticals's Market Cap?

(NASDAQ: SLRX) Salarius Pharmaceuticals's market cap is $2.28M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Salarius Pharmaceuticals's market cap is calculated by multiplying SLRX's current stock price of $0.53 by SLRX's total outstanding shares of 4,314,433.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.